Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
31 results about "Menstrual bleeding" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Tranexamic acid formulations with reduced adverse effects
InactiveUS20090017114A1Minimize and eliminate undesirable gastrointestinal side effectMinimize and prevent dissolutionBiocidePowder deliveryIntestinal structureSide effect
Tranexamic acid formulated in an oral dosage form with at least one agent that decreases tranexamic acid release in the stomach. Such formulations minimize nausea, vomiting, and other adverse gastric effects that may accompany tranexamic acid therapy, for example, to treat heavy menstrual bleeding. One embodiment is an extended release formulation with waxes, polymers, etc. that prevent a bolus release of tranexamic acid in the stomach. An alternative embodiment is a delayed release formulation with polymers that prevent release of tranexamic acid in the acid environment of the stomach and delay its release until the formulation reaches the less acid environment of the intestines. Such formulations enhance patient compliance with therapy because adverse effects of tranexamic acid therapy are reduced.
Owner:FERRING BV
Menorrhagia Instrument and Method for the Treatment of Menstrual Bleeding Disorders
Disclosed is a Menorrhagia Instrument and methods for the treatment of menstrual bleeding disorders.
Owner:FERRING BV
Tranexamic acid formulations with reduced adverse effects
InactiveUS20050025825A1Minimize and eliminate undesirable gastrointestinal side effectMinimize and prevent dissolutionBiocideOrganic active ingredientsIntestinal structureNausea sickness
Tranexamic acid formulated in an oral dosage form with at least one agent that decreases tranexamic acid release in the stomach. Such formulations minimize nausea, vomiting, and other adverse gastric effects that may accompany tranexamic acid therapy, for example, to treat heavy menstrual bleeding. One embodiment is an extended release formulation with waxes, polymers, etc. that prevent a bolus release of tranexamic acid in the stomach. An alternative embodiment is a delayed release formulation with polymers that prevent release of tranexamic acid in the acid environment of the stomach and delay its release until the formulation reaches the less acid environment of the intestines. Such formulations enhance patient compliance with therapy because adverse effects of tranexamic acid therapy are reduced.
Owner:XANODYNE PHARMACEUTICALS INC +1
Methods of extended use oral contraception
A method of female contraception involves administering a combination of estrogen and progestin for 60-110 consecutive days in which the daily amounts of estrogen and progestin are equivalent to about 5-35 mcg of ethinyl estradiol and about 0.025 to 10 mg of norethindrone acetate, respectively. The advantages include less menstrual bleeding, less patient anemia, less total exposure to medication, higher compliance rates and more lifestyle convenience for patients.
Owner:TEVA WOMENS HEALTH
Tranexamic acid formulations with reduced adverse effects
ActiveUS20060127476A1Minimize and eliminate undesirable gastrointestinal side effectMinimize and prevent dissolutionBiocidePeptide/protein ingredientsNausea sicknessPatient compliance
Tranexamic acid formulated in an oral dosage form with at least one agent that decreases tranexamic acid release in the stomach. Such formulations minimize nausea, vomiting, and other adverse gastric effects that may accompany tranexamic acid therapy, for example, to treat heavy menstrual bleeding. One embodiment is an extended release formulation with waxes, polymers, etc. that prevent a bolus release of tranexamic acid in the stomach. An alternative embodiment is a delayed release formulation with polymers that prevent release of tranexamic acid in the acid environment of the stomach and delay its release until the formulation reaches the less acid environment of the intestines. Such formulations enhance patient compliance with therapy because adverse effects of tranexamic acid therapy are reduced.
Owner:AMRING PHARM INC
Methods of treating heavy menstrual bleeding
The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.
Owner:ABBVIE INC
KGM aremisia argyi glutinous rice ball and preparation method thereof
InactiveCN105104939AOvercoming easy aging and hardeningOvercome efficiencyFood ingredient functionsFood preparationCold painVegetable oil
The present invention relates to a KGM aremisia argyi glutinous rice ball and a preparation method thereof, and belongs to the technical field of food. The preparation method comprises: inner stuffing preparation, glutinous rice ball outer layer surface skin preparation, and glutinous rice ball preparation, wherein the inner stuffing preparation method comprises preparing spare vegetable oil, preparing composite syrup, cooking, cooking and discharging out of pot, the glutinous rice ball outer layer surface skin preparation method comprises treating aremisia argyi, blending a slurry, steaming, cooking a syrup, mixing the slurry and the syrup, and blending, and the glutinous rice ball preparation method comprises stuffing shaping and packaging. According to the present invention, the product contains the aremisia argyi being subjected to the bitterness removing treatment, such that the taste is soft and smooth, and the health effects of qi and blood regulating, menstrual bleeding warming, meridian warming, cold-dampness dredging, cold pain stopping and the like are provided; and the KGM is used to replace most of the glutinous rice powder, such that the disadvantages of easy aging, easy hardening, low production efficiency, single raw material and the like of the traditionally glutinous rice cake are overcome; and the product quality is excellent, the long time storage and market circulation can be ensured, consumers can instantly eat the product after unpacking, and the product has sweet and delicate taste and is the health food suitable for all people.
Owner:FUJIAN AGRI & FORESTRY UNIV
Treatment of Excessive Menstrual Bleeding Associated with Uterine Fibroids
The present invention relates generally to benign gynecological diseases and in particular to a method and compositions for reducing heavy menstruation associated with said gynecological diseases following treatment with vascular occlusion methods or thermal related treatment methods.
Owner:PREGLEM
Medicine for treating functional uterine bleeding and method for preparing the same
InactiveCN101112481AMenstrual cycle improvementMenstrual improvementHeavy metal active ingredientsUnknown materialsDiseaseSide effect
The present invention relates to a drug for treating dysfunctional uterine bleeding, the India madder root, Sanguis Draconis and carbonized human hair are mixed and smashed into the fine powder, the Chinese angelica, baical skullcap root, trogopterus dung, cattail pollen, south dodder seed etc. are boiled by water and then filtered and condensed into the thick paste, the drug powder is added for even mixing, finally the product is prepared by smashing and filling in the capsule. The drug of the present invention has the effects of nourishing blood, cooling blood, activating blood circulation, removing blood stasis and hemostasis, which is applicable to the treatment of the advanced menstruation of women, large amount of menstrual bleeding or large amount of uterine bleeding caused by contraceptive ring embedding and drug abortion and other diseases; the present invention has the advantages of easy administration, accurate efficacy and no toxicity or side effects etc. The total effective rate can reach 96.0 percent through the clinical efficacy observations of 100 cases of patients with dysfunctional uterine bleeding.
Owner:THE SECOND HOSPITAL OF SHANXI MEDICAL UNIV
Methods of Treating Heavy Menstrual Bleeding
ActiveUS20210154207A1Reduce fatigueReduce painOrganic active ingredientsSexual disorderButyratePhenyl group
The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.
Owner:ABBVIE INC
Methods of treating heavy menstrual bleeding
The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.
Owner:ABBVIE INC
Extended estrogen dosing contraceptive regimen
A method of contraception that provides for sequentially administering to a female of child bearing age: (a) a first composition containing a progestin in an amount equivalent to about 0.3 to about 1.5 mg norethindrone acetate and an estrogen in an amount equivalent to about 5 to about 20 mcg of ethinyl estradiol for about 22 to about 26 days; (b) a second composition containing an estrogen in an amount equivalent to about 5 to about 20 mcg of ethinyl estradiol for about 2 to about 3 days and an optional third composition that is a placebo provided that (i) if estrogen administration is continuous then the first composition is administered for 25 to 26 days, the second composition is administered for 2 to 3 days and no third composition is administered and (ii) if estrogen administration is not continuous then the first composition is administered for 22 to 24 days, the second composition is administered for 2 to 3 days and the third composition is administered for 1 to 4 days. The total cycle length is 28 days, with the first composition administered on day 1 of the menstrual cycle, defined as the first day of menstrual bleeding, or on the first Sunday after the first day of the menstrual cycle.
Owner:APTALIS PHARMA
Treatment of excessive menstrual bleeding associated with uterine fibroids
The present invention relates generally to benign gynecological diseases and in particular to a method and compositions for reducing heavy menstruation associated with said gynecological diseases following treatment with vascular occlusion methods or thermal related treatment methods.
Owner:PREGLEM
Indole derivatives useful as progesterone receptor modulators
The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment or prevention of disorders and diseases mediated by agonists and antagonists of the progesterone receptor. The clinical uses of these compounds are related to contraception, the treatment and / or prevention of secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis; polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, or minication of side effects of cyclid menstrual bleeding. Additional uses of the invention include stimulation of food intake.
Owner:JANSSEN PHARMA NV
Indole derivatives useful as progesterone receptor modulators
The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment or prevention of disorders and diseases mediated by agonists and antagonists of the progesterone receptor. The clinical uses of these compounds are related to contraception, the treatment and / or prevention of secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis; polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, or minication of side effects of cyclid menstrual bleeding. Additional uses of the invention include stimulation of food intake.
Owner:JANSSEN PHARMA NV
A kind of traditional Chinese medicine medicament for treating gynecological metrorrhagia
ActiveCN104069463BQuick resultsOptimizationHeavy metal active ingredientsMammal material medical ingredientsLong term treatmentsScutellariae radix
Owner:仵爱涛
Methods of treating uterine fibroids and endometriosis
ActiveCN110312512AOrganic active ingredientsPharmaceutical delivery mechanismVasomotor symptomPyridazine
Methods for treating uterine fibroids, endometriosis, adenomyosis, or heavy menstrual bleeding in a subject, which include administering to the subject from 10 mg to 60 mg per day of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea, and from 0.01 mg to 5 mg per day of a hormone replacement medicament. The present disclosure has methods for reducing menstrual bleeding in a subject, reducing bone mineral density loss in a subject caused by administering a GnRH antagonist to the subject, suppressing sex hormones in a subject, reducing vasomotor symptoms or hot flashes in a subject, and reducing symptoms of decreased libido in a subject having uterine fibroids, endometriosis, or adenomyosis. Further provided are methods of maintaining blood glucose profile, maintaining lipid profile, and / or maintaining bone mineral density in a pre-menopausal woman being treated for one or moreconditions or symptoms of endometriosis, adenomyosis, uterine fibroids, or heavy menstrual bleeding; and methods of contraception and treating infertility.
Owner:梦欧文科学有限责任公司 +1
Prediction of bleeding patterns in women after insertion of an intrauterine active-ingredient-releasing system
InactiveUS20190029875A1More computing powerImprove computing powerMedical simulationMedical data miningUterusBULK ACTIVE INGREDIENT
Provided are systems, methods, and computer programs for predicting the menstrual bleeding pattern of a woman using an intrauterine active-ingredient-releasing system. Some embodiments comprise acquiring data on the bleeding pattern of a woman during a period of time beginning with insertion of an intrauterine active-ingredient-releasing system and acquiring one or a plurality of predictor values. Some embodiments include determining a future bleeding pattern of the woman based a classification model configured to classify the woman in one of several bleeding pattern categories. Additionally, some embodiments may comprise displaying the determined future bleeding pattern to one or more of the woman or a physician.
Owner:BAYER AG
Blood activating and stasis removing Chinese medicinal formula for regulating little menstrual bleeding
InactiveCN108904699AProtect healthGood curative effectUnknown materialsSexual disorderPremenstrual symptomsBran
The invention discloses a blood activating and stasis removing Chinese medicinal formula for regulating little menstrual bleeding and a decoction method. The Chinese medicinal formula comprises the following components by weight: white hyacinth bean, licorice, fructus aurantii stir-fried with bran, glossy privet fruit, viscum coloratum, stir-fried salted eucommia ulmoides, polygonatum, radix astragali, codonopsis pilosula, Chinese angelica, prepared rhizome of rehmannia, Ligusticum wallichii, radix paeoniae alba, peach kernel, safflower, stir-fried cattail pollen, trogopterus dung and motherwort. According to the invention, compatibility of the white hyacinth bean, licorice, fructus aurantii stir-fried with bran, glossy privet fruit, viscum coloratum, stir-fried salted eucommia ulmoides, polygonatum, radix astragali and codonopsis pilosula has the efficacy of nourishing yin and benefiting kidney, tonifying Qi and soothing liver, promoting menstruation and harmonizing blood. The primaryefficacy of Chinese angelica is blood nourishing and menstruation regulating, and also has the efficacy of complexion lustering and skin moistening. Compatibility of prepared rhizome of rehmannia andChinese angelica can enhance the blood replenishing and blood activating efficacy of Chinese angelica. Ligusticum wallichii can affect the endocrine system, and alleviate breast discomfort, anxiety,depression and other premenstrual symptoms. Radix paeoniae alba can nourish blood and emolliate liver. Stir-fried cattail pollen can promote blood circulation and disperse stasis. trogopterus dung canbe used for treating stagnation of blood stasis and bleeding caused by escape of blood from vessels and channels. And motherwort can promote blood circulation, dispel stasis, regulate menstruation and eliminate water.
Owner:THE SECOND HOSPITAL AFFILIATED TO WENZHOU MEDICAL COLLEGE
Health tea for adjusting blood stasis type delayed menstruation abdominal pain
InactiveCN105519725AEffective treatment of abdominal distension and pain, dark menstruationEffective treatment for lumps, depression and other symptomsOrganic active ingredientsAntipyreticBiological activationEffective treatment
The present invention relates to a health tea, particularly to a health tea for adjusting blood stasis type delayed menstruation abdominal pain, wherein plant Chinese herbs are adopted as raw materials, and the raw materials comprise, by weight, 10-15 g of fresh rosa chinensis jacq, 1-5 ginger slices, and 4-6 g of brown sugar. According to the present invention, the health tea can be taken for a long time, has effects of blood circulation activation and blood stasis dissipating, cold expelling and menstruation regulating, and can effectively treat blood stasis type delayed menstruation abdominal pain, dark and block-like menstrual bleeding, depression and other symptoms.
Owner:林少梅
Medicine for treating functional uterine bleeding and method for preparing the same
InactiveCN101112481BImprove efficacyGood treatment effectUnknown materialsCapsule deliveryDiseaseClinical efficacy
The present invention relates to a drug for treating dysfunctional uterine bleeding, the India madder root, Sanguis Draconis and carbonized human hair are mixed and smashed into the fine powder, the Chinese angelica, baical skullcap root, trogopterus dung, cattail pollen, south dodder seed etc. are boiled by water and then filtered and condensed into the thick paste, the drug powder is added for even mixing, finally the product is prepared by smashing and filling in the capsule. The drug of the present invention has the effects of nourishing blood, cooling blood, activating blood circulation,removing blood stasis and hemostasis, which is applicable to the treatment of the advanced menstruation of women, large amount of menstrual bleeding or large amount of uterine bleeding caused by contraceptive ring embedding and drug abortion and other diseases; the present invention has the advantages of easy administration, accurate efficacy and no toxicity or side effects etc. The total effectiverate can reach 96.0 percent through the clinical efficacy observations of 100 cases of patients with dysfunctional uterine bleeding.
Owner:THE SECOND HOSPITAL OF SHANXI MEDICAL UNIV
Scented tea capable of beautifying features and nourishing faces, and preparation method of scented tea
The invention discloses scented tea capable of beautifying features and nourishing faces, and a preparation method of the scented tea, and belongs to processing of scented tea. According to the scented tea capable of beautifying features and nourishing faces, red jujubes, rose flowers, carnations, peach flowers, jasmine flowers, roselle scented tea, cymbopogon citratus and black Chinese wolfberryfruits are used as raw materials, wherein the peach flowers have the effects of beautifying features, nourishing faces, regulating menstrual bleeding, reducing weight and slimming; the roselle flowerscontain anthocyan, so that the roselle flowers can resist oxidation, nourish faces and remove freckles; tea polyphenols and tea pigments can beautify features, nourish faces, clean and whiten skins and resist ageing; vitamin C and cyclic adenosine monophosphate can promote skin cell metabolism, prevent melanin pigmentation and enable skins to be clean, white, fine and smooth so as to achieve thefeature-beautify skin-protecting efficacy of whitening skins and dispelling freckles. The components mutually cooperate in fragrance, and are warm in nature.
Owner:芜湖绿而优农业科技有限公司
Selective progesterone receptor modulator (SPRM) regimen
The invention is directed to a pharmaceutical composition comprising a progesterone receptor antagonist namely (11beta,17beta)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one for the treatment and / or prophylaxis of Uterine Fibroids (myomas, uterine leiomyoma) that is administered to a patient diagnosed with Uterine Fibroids following a specific regimen. Additionally, the invention is directed to a method for treating Uterine Fibroids (myomas, uterine leiomyoma) and / or for reducing Uterine Fibroids (myomas, uterine leiomyoma) size and symptoms related to Uterine Fibroids following a specific regimen as well as treatment of Heavy Menstrual Bleeding (HMB).
Owner:BAYER PHARMA AG
Selective progesterone receptor modulator (SPRM) regimen
The invention is directed to a pharmaceutical composition comprising a progesterone receptor antagonist namely (11beta,17beta)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one for the treatment and / or prophylaxis of Uterine Fibroids (myomas, uterine leiomyoma) that is administered to a patient diagnosed with Uterine Fibroids following a specific regimen. Additionally, the invention is directed to a method for treating Uterine Fibroids (myomas, uterine leiomyoma) and / or for reducing Uterine Fibroids (myomas, uterine leiomyoma) size and symptoms related to Uterine Fibroids following a specific regimen as well as treatment of Heavy Menstrual Bleeding (HMB).
Owner:BAYER PHARMA AG
Application of exosome from endometrium stem cells to medicines for treating acute lung injury
The invention discloses an application of exosome from endometrium stem cells to medicines for treating acute lung injury. The endometrium stem cells are from menstrual bleeding of women. According tothe application disclosed by the invention, the endometrium stem cells are convenient to obtain and rich in source, an endometrium stem cell exosome preparation is simple to prepare, and an infusiontechnique is simple, convenient and easy to operate; and the exosome has significant effects on improving lung functions and reducing inflammation during acute lung injury, and has important clinicalsignificance and great application prospects.
Owner:HANGZHOU S EVANS BIOSCI LTD
Methods of treating heavy menstrual bleeding
PendingCN112261942AReduce fatigueReduce takingOrganic active ingredientsSexual disorderEthyl groupPhenyl group
The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof,in combination with estrogens and progestogens.
Owner:ABBVIE INC
Traditional Chinese medicine wine and preparation method thereof
InactiveCN104706757AThe brewing method is simpleAntipyreticAnalgesicsEphedra sinicaAconitum carmichaeli
The present invention discloses a traditional Chinese medicine wine and a preparation method thereof, and belongs to the field of traditional Chinese medicines. The traditional Chinese medicine wine comprises, by weight, 10-20 parts of papaya, 4-6 parts of aconitum carmichaelii, 10-14 parts of radix angelicae pubescentis, 10-20 parts of kadsura interior, 5-10 parts of fructus xanthii, 2-6 parts of ephedra sinica stapf, 3-8 parts of cynanchum otophyllum, 3-8 parts of milkvetch root, 2-8 parts of tuckahoe, 2-6 parts of licorice root, 10-14 parts of cortex acanthopanacis, 8-12 parts of clematis chinensis, 6-10 parts of sambucus williamsii, and 100-300 parts of white spirit. The preparation method comprises: dipping the herbs in the white spirit, sealing, soaking for 15-25 days, and filtering to remove the herb residues to obtain the traditional Chinese medicine wine. The traditional Chinese medicine wine of the present invention has effects of wind-evil dispelling, dampness eliminating, meridian smoothing, and menstrual bleeding loosening, effectively removes joint pain, deformation and other symptoms of rheumatoid, and further has the characteristic of simple infusing method.
Owner:ZIBO DEV ZONE YADA PHARMA
Traditional Chinese medicine for treating female hypomenorrhea caused by qi deficiency and blood deficiency
InactiveCN108686081AImprove physical conditionLess menstrual flowPill deliveryPharmaceutical non-active ingredientsSide effectTherapeutic effect
The invention relates to a traditional Chinese medicine for treating female hypomenorrhea caused by qi deficiency and blood deficiency, wherein the technical scheme is that the traditional Chinese medicine is prepared from the following bulk drugs by weight: 10-40 parts of Radix Rehmanniae Preparata, 15-40 parts of Radix Paeoniae Alba, 30-50 parts of Angelica sinensis, 20-50 parts of ginseng, 20-40 parts of Atractylodes macrocephala, 20-40 parts of tuckahoe, 10-40 parts of Cyperus rotundus L, and 20-60 parts of Leonurus artemisia. According to the present invention, the traditional Chinese medicine is suitable for the significantly reduced menstrual volume of less than 30 ml or the menstrual period of less than 2 days, little menstrual bleeding and other symptoms, can improve the qi deficiency and the blood deficiency of female bodies through blood enriching, nourishing, essence benefiting, marrow enriching, blood nourishing, ying-wei regulating, spleen strengthening and qi benefitingso as to relieve and cure hypomenorrhea, further has characteristics of significant treatment effect, no chemical component, no hormones, no side effect, easy taking, easy absorbing, quick effect andlow price, and is the pure traditional Chinese medicine preparation; and the clinical application observation results prove that the traditional Chinese medicine composition has characteristics of high efficiency and long acting.
Owner:洛阳士雄聚元医疗集团股份有限公司
Indole derivatives useful as progesterone receptor modulators
The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment or prevention of disorders and diseases mediated by agonists and antagonists of the progesterone receptor. The clinical uses of these compounds are related to contraception, the treatment and / or prevention of secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis; polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, or minication of side effects of cyclid menstrual bleeding. Additional uses of the invention include stimulation of food intake.
Owner:JANSSEN PHARMA NV
Methods of treating heavy menstrual bleeding
Owner:ABBVIE INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com